Vol. 6, Issue 2, Part B (2024)

Recurrent Implantation Failure (RIF) poses a significant challenge in the management of infertility. We report a novel approach using Thymosin alpha 1 (TA 1) in a 32-year-old female with unexplained RIF. Despite previous failed IVF attempts and various interventions, including endometriosis treatment, ovarian platelet rich plasma therapy and Oocyte Donor (OD)-ICSI cycles along with other adjuvant therapies such as intralipids, steroids, low molecular weight heparin (LMWH), Hydroxychloroquine (HCQ), still pregnancy remained elusive. Immuno-profiling revealed Type 1 T helper cells (TH1) dominance, leading to TA 1 therapy alongside Hormone Replacement Therapy (HRT). TA 1, known for immune modulation, was administered as 13 injections before embryo transfer. Patient achieved a successful pregnancy, indicating TA 1 potential in immune-mediated RIF cases. Thymosin alpha’s safety and efficacy in pregnancy warrants further investigation through prospective trials for broader validation.